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Abstract
There has recently been intense interest in the clinical measurement of tissue factor (TF)-positive
microparticles (MPs) in clinical disease states. This interest has been driven by the demonstration of
an putative role for circulating TF-positive MPs in animal models of thrombus propagation. Both
immunological and functional assays for MP-TF have been described. While each approach has its
own advantages and drawbacks, neither has yet been truly established as the ‘gold standard’.
Heterogeneity of TF-bearing MPs, such as the variable co-expression of surface phosphatidylserine,
may determine not only their procoagulant potential, but also additional properties including rate of
clearance from the circulation.
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The landmark study of Giesen and colleagues is generally acknowledged as the first
demonstration of the existence of circulating MPs containing functionally intact TF in the blood
of healthy subjects (1). Until that time, the prevailing paradigm had been that constitutive TF
expression in healthy individuals is confined to cells in the extravascular compartment, only
coming into contact with factor VII/VIIa after vessel injury (2). The discovery that endotoxin
induces TF expression in monocytes served to maintain the focus on intravascular cell-
bound TF in certain disease states, such as sepsis (3). Although a few earlier studies had
demonstrated the presence of detectable blood-borne TF activity in healthy subjects (4,5), it
was not specifically localized to the MP fraction, with the possible exception of the report that
about one third of circulating ‘soluble’ TF antigen was present in a sedimentable fraction of
plasma (6).
Elegant studies using intra-vital microscopy to track the origin and accumulation of
endogenous TF on the luminal aspect of experimental thrombi in the microvasculature of small
animal models soon followed (7). These studies appeared to establish an important role for
circulating MP-borne, but not leucocyte-borne TF (8) in the genesis of fibrin formation in
vivo. However, there remained some discrepancies in the results of studies designed to evaluate
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the cellular source (i.e. hematopoietic vs. vessel wall) of MP-TF during thrombus formation.
When laser injury was used to initiate clot formation in the microvasculature, circulating TF
appeared to be required for normal fibrin generation (9). However, in large vessel thrombosis
models, such as in the carotid artery following photochemical injury, vessel wall TF appeared
to be much more important than TF derived from hematopoietic sources (10). These
inconsistencies have been interpreted to be a result of the particular experimental trigger used
to initiate thrombus formation, specifically whether the triggering stimulus leads to endothelial
denudation and exposure of the high concentrations of sub-endothelial TF (11). Arguably,
venous thrombosis is a more relevant model in which to study the role of circulating TF; unlike
many forms of arterial thrombosis, it is generally believed that vascular endothelium below
the thrombus remains intact, thereby raising the question as to the source of TF required to
initiate thrombosis. Small animal models have demonstrated the presence of abundant TF
antigen embedded within thrombi and within adherent leucocytes, (12-14) which appears to
correlate with reports in human thrombi (15). However, this evidence clearly does not establish
that circulating MPs are the source of the accumulated TF, because antigenically-detectable
intravascular TF may also include alternatively spliced TF (asTF), first described in vivo in
2006 (16). In this isoform, the transmembrane and cytoplasmic domains are replaced by a
unique 40 amino acid C-terminal domain. Although this soluble form of TF probably does not
retain any significant amount of procoagulant activity, it may be important in other biological
settings, such as in the promotion of angiogenesis (17). Inhibition of TF expression or synthesis
prevented extension of the fibrin clot in some models of venous thrombosis (13,18). Mice
expressing very low levels of hTF showed reduced thrombus size in the IVC ligation model,
but no contribution from hematopoietic cell derived, TF-positive MPs could be demonstrated
(10).
These animal models remain the best available evidence that circulating MP-TF is an important
mediator -- and thus a potential biomarker -- of thrombotic risk in disease states. In addition,
studies correlating the cellular source(s) of MP-TF detected in vivo with in vitro observations
add weight to the rationale for studying the role of circulating MP-TF in disease states. Thus,
the in vitro demonstration that cancer cells generate TF positive MPs (19) appears to have been
confirmed by the finding of circulating MPs expressing tumor-specific antigens in the plasma
of patients with cancer (20,21). Similarly, the detection of circulating monocyte-derived MPs
expressing TF following exposure to endotoxin in vivo (22) is consistent with earlier in vitro
studies on LPS-stimulated monocytes (23).
In this narrative, I will briefly describe the approaches that have been developed to detect and
quantify circulating MP-TF in humans, and discuss a few areas in which our existing
knowledge base requires additional data.
Methods of MP-TF detection
Most commonly, MP-TF is assayed on circulating MPs in plasma, although other body fluids
have also been shown to contain TF-bearing MPs that may have diagnostic and/or prognostic
relevance (24). Not all methods of MP-TF detection require a MP isolation step, but at a
minimum, there is a need to prepare cell-free samples from blood or the body fluid under study.
Centrifugation speed, which must be sufficient to remove contaminating cells, but not the MPs
of interest, is a critical variable. Other important pre-analytical variables include: 1] the
venipuncture method by which the sample was obtained (since contamination by TF originating
from skin and vessel wall cells can be significant, given the minute quantities of TF being
measured); 2] the anticoagulant into which the samples are drawn (since calcium chelators may
dissociate bound TFPI, among other effects); 3] and whether the samples are analyzed fresh
or after freezing (since freeze-thawing may ‘decrypt’ TF expression in the membrane of MPs
(25)).
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When employed, the specific conditions used to isolate MPs from plasma also vary
considerably among research laboratories (26). Few published studies have systematically
evaluated the pre-analytical variables that may influence MP-TF detection (25), but it remains
an important area for future standardization if MP-TF assays are ever to enter the clinical
diagnosis arena.
Broadly speaking, MP-TF assays can be classified as either immunological or functional
methods that we will briefly summarize.
A] Immunological
Immunological methods detect TF antigen on the surface of MPs using specific antibodies or
other probes that have been labeled with a detector, such as a fluorescent tag. In flow cytometry,
an operational definition is used to detect MPs. The usual criteria include events that; 1] are
<1μm in size; 2] express phosphatidylserine (PS), which is usually detected by binding of
labeled Annexin V or lactadherin; 3] express antigens that characterize the cell of origin; and
4] may be removed by high speed centrifugation (at least 18,000g for 30 minutes (27)). TF
may be detected on MPs using specific labeled antibodies, but this approach clearly imparts
no information about whether the TF is functionally active, and it is at best semi-quantitative.
Flow cytometry also suffers from the fact that particles <0.5μm are smaller than the wavelength
of the laser light used to detect them, and thus they may not be detectable. Therefore, there has
been recent interest in other physical methods to detect MPs. These approaches have included
dynamic light scattering, capillary electrophoresis with laser-induced fluorescence detection,
impedance-based flow cytometry, and atomic force microscopy. In theory, all of these methods
can be adapted to detect TF and other antigens on the MP surface, although these studies are
largely still in their infancy.
B] Functional
Since the earliest demonstration of MP generation by platelets, it has been known that PS
expression on MPs contributes to thrombin generation by facilitating assembly of the
prothrombinase complex (28). Membrane PS exposure is also important in ensuring that the
full procoagulant potential of MP-TF is expressed, and it is an important component of the
‘decryption’ process of TF (Figure 1a). TF-independent procoagulant activity of MPs in plasma
may be measured using prothrombinase assays on MPs isolated from cell-free plasma by a
capture technique (29) or by high speed centrifugation. Similarly, TF-dependent procoagulant
activity may be assayed following isolation by capture (22) or high-speed centrifugation (30).
Finally, global assays of thrombin generation such as calibrated automated thrombography
have been adapted to measure endogenous MP-TF activity in platelet rich or platelet poor
plasma (31).
Analytical variables to be considered include not only the sensitivity, but also the specificity
of the TF assay. Specificity here is defined as the TF dependence of factor VIIa activation of
factor X. In practice, this is usually determined by the addition of a specific blocking antibody
to TF in parallel wells. Thus, for example, using the capture assay for MP-TF activity (22),
about two thirds of the VIIa-dependent activation of factor X was inhibited by a blocking
antibody to TF, whereas >95% of Xa generation was TF-dependent in MPs obtained from
plasma following endotoxin exposure (Figure 1b).
Is phosphatidylserine exposure ubiquitous in MPs?
A number of in vitro studies on isolated or cultured cells have shown that MP formation is
associated with loss of the membrane phospholipid asymmetry that prevails in healthy cells.
Cellular activation or apoptosis induce calcium-dependent activation of scramblase and
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floppase, and inhibition of flippase activities, with the net result that phosphatidylserine (PS)
is exposed on the outer leaflet of the MP membrane (32). Thus, to a large extent, PS exposure
on the surface of MPs has become synonymous with the definition of a MP, and this property
is exploited in many of the immunological and functional assays for MP-TF already described.
However, the processes of membrane PS exposure and MP generation can be dissociated in
isolated cells (33). Furthermore, both in sickle cell disease and in the human endotoxemia
model, we detected an increased number of PS-negative MPs (as judged by the absence of
annexin V binding) in vivo (22,34). Others have similarly reported the presence of PS-negative
MPs in vivo (35). In vitro, we and others have shown that PS expression on platelet-derived
MPs varies according to the stimulus used to generate them (36,37). In cultured endothelial
cells also, the PS content of MPs released into the supernatant may depend on whether they
were produced by agonists that result in activation or apoptosis (38).
PS exposure is potentially important not only from the standpoint of the inherent MP
procoagulant potential, but also with respect to MP clearance. Much has been learned about
the importance of PS exposure on apoptotic cells or senescent red cells, where it appears to be
a critical ligand that interacts with several receptors on phagocytic macrophages, resulting in
removal of the apoptotic cells (39). Endogenous lactadherin may be an important ‘tag’, binding
to PS on MPs and marking them for clearance (40). Theoretically therefore, PS-negative MPs
may evade this fate, and could serve as a distinct long lasting ‘surveillance reservoir’ of MPs;
TF on these MPs would become decrypted after binding to a PS-expressing membrane, such
as the surface of an activated platelet (7,41,42).
What is needed to prove that MP-TF plays an important role in thrombus
formation?
The concept that a clinically significant concentration of TF circulates in the plasma of healthy
subjects has been questioned using sensitive and specific assays. These studies concluded that
the concentration of functionally active TF in whole blood of healthy subjects is < 20 fM, which
was the lower concentration limit for initiation of coagulation in contact pathway inhibited
blood (43). However, other studies have demonstrated that while the addition of 100 fM TF to
whole blood is insufficient to initiate coagulation under static conditions, it will promote fibrin
formation under physiologic flow conditions (44). Undoubtedly, one of the difficulties in
comparing studies is the lack of a TF standard to ensure that comparable concentrations of TF
are being evaluated. As such, technical issues with the various assays, including the
development of an internationally recognized TF standard, remain an important priority.
Although there are now many cross-sectional studies documenting increased concentrations
of MP-TF in a variety of autoimmune, inflammatory and malignant disease states, there are
limited data from prospective studies demonstrating that MP-TF levels can be considered a
true marker of thrombotic risk. Thus far, it is unclear whether the lack of such data is the result
of technical limitations or the lack of such a causative association.
Finally, although recent studies on circulating TF have mostly focused on MP-associated TF,
less than 5% of the total circulating pool of TF is associated with MPs (45). Furthermore, high-
risk situations for thrombosis -- such as the postoperative period following total knee
replacement surgery -- are associated with a temporally relevant increase in mononuclear cell-
associated TF activity (45). Therefore, clinical studies focusing on the causative relationship
between MP-TF and thrombotic disease should not neglect a possible role for cell-associated
TF.
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Figure 1a: Cartoon representing the hierarchical procoagulant activity of microparticles
(MPs). Depending on their cellular origin, the procoagulant potential of circulating MPs may
be either tissue factor (TF)-dependent and/or TF-independent. The MP on the left hand side
that maintains PS on the inner leaflet, and does not express TF, would express very little (if
any) procoagulant activity. The negative bars (-) adjacent to ‘PS’ indicate the surface
expression of negatively charged PS. MPs expressing both TF and negatively charged surface
phosphatidylserine (PS), as represented by the particle on the extreme right hand side, would
theoretically contribute most to fibrin generation. Figure courtesy of Dr Nigel Mackman.
Figure 1b: TF-dependent vs. TF-independent procoagulant activity on circulating MPs.
Platelet free plasma was obtained from human volunteers exposed to endotoxin, and assayed
for MP-TF activity as previously described (22). The concentration of factor Xa generated
following the addition of 5 nM factor VIIa and 150 nM factor X for 6 hours is shown on the
y-axis. Both at baseline and at 4 hours after LPS administration, the Xa generated with and
without the addition of an inhibitory polyclonal antibody to TF is shown.
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